Health Care/Hospital

EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide

PROVIDENCE, R.I., Dec. 9, 2025 /PRNewswire/ -- EpiVax, Inc. , with U.S. Food and Drug Administration (FDA) and CUBRC, Inc. (Buffalo, NY) scientist collaborators, announces the publ...

2025-12-09 03:11 1648

Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium

* In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as well as in both metastatic and early stage breast cancer. FLORENCE, Italy and NEW YORK, Dec. 8, 2025 /PRNewswire/ -- The Menarini Gro...

2025-12-09 03:05 2326

Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement – – Strong activity observed across ESA-refractory and ESA-intolerant patients, and across mutation and morphology subtypes – – Favorable safety profile with no treatment-related serious adverse e...

2025-12-08 22:22 1834

PT Fapon and PT Bio Farma Forge Strategic Partnership to Advance IVD Localization and Innovation in Indonesia

DONGGUAN, China, Dec. 8, 2025 /PRNewswire/ -- PT Fapon Bioindustries Indonesia (referred to as "PT Fapon") and the Indonesian state-owned pharmaceutical holding company PT Bio Farma (Persero) (referred to as "Bio Farma") officially signed a cooperation agreement at Fapon's headquarters inDongg...

2025-12-08 20:47 1846

Servier's Voranigo® (vorasidenib) Receives Prix Galien Awards Across Multiple Regions

* Voranigo® has been awarded the Prix Galien USA, the Prix Galien Poland and the Prix Galien Bridges Awards for Best Product for Orphan/Rare Diseases. * These awards across several geographies recognize the progress represented by Voranigo® for patients living with glioma. SURESNES, France, De...

2025-12-08 20:24 1788

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight

-  ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no observed plateau for weight loss. -  ASC30 titrated weekly to target dose demonstrated approximately one-half the rate of vomiting observed w...

2025-12-08 17:40 3344

Qualcomm Highlights Edge AI Innovation at Qualcomm AI Program for Innovators (QAIPI) 2025 - APAC Demo Day and Sets the Stage for 2026

Showcasing transformative edge AI innovations across robotics, healthcare and smart city solutions SEOUL, South Korea, Dec. 8, 2025 /PRNewswire/ -- Qualcomm Technologies, Inc. hosted the Qualcomm AI Program for Innovators (QAIPI) 2025 – APAC Demo Day in Seoul, where 15 shortlisted startups from J...

2025-12-08 16:28 2399

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

* Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1 * Holistic benefit: secondary endpoints showed significant and clinically meaningful improvements ...

2025-12-08 15:25 1228

Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

TOKYO, Dec. 8, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximatelyJPY 70 million (USD 460,0001) for the development of a prototype detection test for mpox (formerly known as monkeypox2). Mpox is a viral infectious disease that h...

2025-12-08 09:00 1580

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- AI/ML health-tech startup Respiree has received approval from the Health Sciences Authority (HSA) for its 1Bio™AI-Acute toolbox as a Class B software-as-a-medical device (SaMD). The solution is designed to support healthcare pro...

2025-12-08 08:00 1774

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- ChemLex , a next-generation AI-for-science company, today announced the establishment of its global headquarters and self-driving laboratory inSingapore, alongside the close of aUSD 45 million funding round led by Granite Asia

2025-12-08 08:00 2201

ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate can...

2025-12-08 06:08 1993

Leaders Dental Leads Korea's Prosthodontic Market With Large-Scale 300-Pyeong Production Infrastructure and a "Clinically Integrated Collaboration Model"

SEOUL, South Korea, Dec. 7, 2025 /PRNewswire/ -- Leaders Dental Laboratory, a major force driving the digitalization and large-scale transformation of Korea's dental laboratory industry, is solidifying its leadership with a production facility spanning over 300 pyeong. This extensive infrastructu...

2025-12-07 08:00 2308

/C O R R E C T I O N -- Seegene Inc./

In the news release, "Seegene Establishes French Subsidiary to Expand European Footprint", issued05-Dec-2025 by Seegene Inc. over PR Newswire, we are advised by the company that the first sub-headline should read "France becomes Seegene's eighth overseas sales subsidiary and third inEurope, follo...

2025-12-06 00:00 4779

AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer

-       Ovarian cancer remains an unmet medical need, and experts call for new strategies to define and treat platinum resistance in patients with advanced ovarian cancer[1],[2],[3] SINGAPORE, Dec. 5, 2025 /PRNewswire/ -- At an AbbVie-sponsored symposium at the ESMO Asia Congress 2025, experts g...

2025-12-05 16:00 1493

Post-Disaster Support | Emergency Financial Assistance for Self-Financed Cancer Drugs

HONG KONG, Dec. 5, 2025 /PRNewswire/ -- The Level 5 fire at Wang Fuk House, Tai Po, on 26 November has left nearly 2,000 households homeless and plunged many families into hardship. Recovery and rebuilding after a disaster is a long journey that requires support from all sectors of society. To t...

2025-12-05 14:03 1421

ALL CONEC Selected for Dream Venture Star 11, Prize Award and MOU Scheduled on November 14

SEOUL, South Korea, Dec. 5, 2025 /PRNewswire/ -- ALL CONEC has been selected for the Dream Venture Star (DVS) 11 "Oracle × Uclick Program Business Meetup" support initiative. The official event will take place onNovember 14 at the Daejeon Center for Creative Economy and Innovation, where ALL CONE...

2025-12-05 11:00 1820

Agilent and Monash University Malaysia Mark 15-Year Partnership with New BioDiscovery Hub to Drive Regional Biotech Innovation

Collaboration aimed at accelerating R&D in both small- and large-molecule analysis and building high-impact capabilities in fast-growing Asian markets KUALA LUMPUR, Malaysia, Dec. 5, 2025 /PRNewswire/ -- Agilent Technologies Inc.  (NYSE: A) announced the expansion of the...

2025-12-05 09:30 2888

Renuka Iyer, MD, Named New Chief Medical Officer for National Comprehensive Cancer Network (NCCN)

Acclaimed oncologist from Roswell Park Comprehensive Cancer Center to help lead nonprofit responsible for gold standard guidelines that define and advance cancer care worldwide. PLYMOUTH MEETING, Pa., Dec. 4, 2025 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of ...

2025-12-04 21:04 2009

NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO

* Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistance * The Phase 1 ragistomig study achieved its objective, as the new Q6W extended dosing in...

2025-12-04 20:34 1771
1 ... 46474849505152 ... 541